Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

97.26 +1.20 (+1.25%)
Streaming Delayed Price Updated: 3:13 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Which stocks are gapping on Wednesday? ↗
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
8 Analysts Have This To Say About Rhythm Pharmaceuticals ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) meets Minervini’s Trend Template with strong technicals and high revenue growth, making it a candidate for growth investors. 
Via Chartmill
News headline image
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) ↗
 
Via Benzinga
News headline image
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? ↗
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty. 
Via Benzinga
News headline image
Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals ↗
 
Via Benzinga
News headline image
Ross Stores To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish ↗
CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025. 
Via Stocktwits
Topics Government
News headline image
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder ↗
Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks. 
Via Benzinga
News headline image
Analyst Expectations For Rhythm Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts ↗
 
Via Benzinga
News headline image
What's Next: Rhythm Pharmaceuticals's Earnings Preview ↗
 
Via Benzinga
News headline image
Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential ↗
Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion 
Via Benzinga
News headline image
Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals ↗
 
Via Benzinga
News headline image
RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 ↗
RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts ↗
 
Via Benzinga
News headline image
The 3 Best Nasdaq Stocks to Buy in May 2024 ↗
Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May. 
Via InvestorPlace
News headline image
Analyst Expectations For Rhythm Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson ↗
The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.